Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Immune Checkpoint Inhibitors
100%
Kidney Transplant Recipients
99%
Kidney Transplant
71%
Kidney Transplantation
58%
Transplantation
41%
Immunosuppression
41%
Transplant Recipients
35%
Alloimmunization
29%
Immune Regulation
29%
T Cells
29%
COVID-19
26%
Transplant Oncology
26%
Kidney Disease
25%
Immune-related Adverse Events (IrAEs)
25%
Cancer Treatment
24%
Nephrologists
24%
In Cancer
24%
Malignancy
24%
Treg
24%
Pretransplant
23%
Acute Kidney Injury
22%
Onconephrology
20%
Nephrotoxicity
20%
Cancer Screening
20%
95% Confidence Interval
19%
Meta-analysis
19%
Dairy-free Diet
19%
Gluten-free
19%
Clinical Outcomes
19%
Oncologists
18%
Solid Organ Transplant Recipients
18%
Immune Checkpoint Therapy
18%
Dialysis
17%
Transplant Rejection
17%
Cancer Patients
17%
Plasma Cell Dyscrasia
16%
Donor-specific Antibodies
16%
Nephrology
15%
Kidney Transplant Rejection
15%
Programmed Cell Death Protein 1 (PD-1)
15%
Face Transplant
15%
MTOR Inhibitor
15%
Transplant Patients
15%
Cell Therapy
15%
Japan
15%
Palliative Care
15%
Novel Therapeutics
15%
Chimeric Antigen Receptor T Cells (CAR-T)
15%
Kidney
14%
Corticosteroids
14%
Medicine and Dentistry
Kidney Graft
96%
Malignant Neoplasm
73%
Immune Checkpoint Inhibitor
67%
Kidney Transplantation
52%
Cancer
46%
Oncology
36%
Immunosuppressive Treatment
31%
Immunotherapy
28%
Nephropathy
27%
Immune-Related Adverse Events
25%
Cancer Therapy
24%
Nephrologist
23%
T Cell
21%
Allograft
20%
Cancer Treatment
17%
Cancer Screening
17%
Interstitial Nephritis
17%
End Stage Renal Disease
17%
Cell Therapy
16%
Nephrology
16%
Kidney Function
16%
Diseases
16%
Biopsy Technique
16%
Plasma Cell Dyscrasia
15%
Proteinuria
14%
Renal Biopsy
14%
Kidney Allograft
14%
Nephrotoxicity
14%
Systematic Review
13%
Meta-Analysis
13%
Regulatory T Cell
13%
Face Transplant
13%
Congenital Nephrotic Syndrome
13%
Hemodialysis
13%
Chronic Kidney Disease
13%
Oncologist
13%
Recurrent Disease
12%
Overall Survival
12%
Acute Kidney Injury
11%
Acute Graft Rejection
11%
Graft Survival
11%
Virus
10%
Calcineurin Inhibitor
10%
Colorectal Carcinoma
10%
Solid Organ Transplantation
10%
Clinician
10%
Nivolumab
9%
Immune Checkpoint Blockade
9%
Adverse Event
9%
Clinical Trial
9%